Forsta AP Fonden Makes New $5.59 Million Investment in Charles River Laboratories International, Inc. (NYSE:CRL)

Forsta AP Fonden purchased a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 15,100 shares of the medical research company’s stock, valued at approximately $5,586,000.

A number of other institutional investors and hedge funds have also made changes to their positions in CRL. Parkside Financial Bank & Trust increased its holdings in shares of Charles River Laboratories International by 6.6% during the second quarter. Parkside Financial Bank & Trust now owns 402 shares of the medical research company’s stock worth $149,000 after buying an additional 25 shares in the last quarter. Centerpoint Advisors LLC increased its holdings in shares of Charles River Laboratories International by 60.0% during the second quarter. Centerpoint Advisors LLC now owns 80 shares of the medical research company’s stock worth $30,000 after buying an additional 30 shares in the last quarter. Archer Investment Corp increased its holdings in shares of Charles River Laboratories International by 13.2% during the second quarter. Archer Investment Corp now owns 257 shares of the medical research company’s stock worth $95,000 after buying an additional 30 shares in the last quarter. Greenleaf Trust increased its holdings in shares of Charles River Laboratories International by 4.2% in the second quarter. Greenleaf Trust now owns 749 shares of the medical research company’s stock valued at $277,000 after purchasing an additional 30 shares in the last quarter. Finally, Oppenheimer & Co. Inc. increased its holdings in shares of Charles River Laboratories International by 2.4% in the second quarter. Oppenheimer & Co. Inc. now owns 1,462 shares of the medical research company’s stock valued at $541,000 after purchasing an additional 34 shares in the last quarter. Hedge funds and other institutional investors own 93.28% of the company’s stock.

A number of analysts recently weighed in on the stock. Wells Fargo & Company raised their price target on shares of Charles River Laboratories International from $375.00 to $470.00 and gave the company an “overweight” rating in a report on Thursday, August 5th. JPMorgan Chase & Co. boosted their price target on Charles River Laboratories International from $375.00 to $390.00 and gave the company an “overweight” rating in a report on Friday, May 28th. Credit Suisse Group upped their price objective on Charles River Laboratories International from $385.00 to $420.00 and gave the stock a “neutral” rating in a research report on Thursday, August 5th. Argus lifted their target price on Charles River Laboratories International from $390.00 to $480.00 and gave the company a “buy” rating in a research report on Monday, August 23rd. Finally, boosted their price target on shares of Charles River Laboratories International from $350.00 to $355.00 and gave the stock a “neutral” rating in a research report on Friday, May 28th. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, Charles River Laboratories International has a consensus rating of “Buy” and a consensus target price of $400.79.

In other Charles River Laboratories International news, VP William D. Barbo sold 12,387 shares of the stock in a transaction that occurred on Friday, August 6th. The stock was sold at an average price of $402.82, for a total transaction of $4,989,731.34. Following the transaction, the vice president now directly owns 4,371 shares in the company, valued at approximately $1,760,726.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Birgit Girshick sold 81 shares of the stock in a transaction that occurred on Monday, September 13th. The stock was sold at an average price of $442.19, for a total value of $35,817.39. Following the transaction, the vice president now owns 30,025 shares in the company, valued at $13,276,754.75. The disclosure for this sale can be found here. Insiders sold 40,900 shares of company stock valued at $16,673,320 in the last ninety days. 1.20% of the stock is currently owned by insiders.

CRL stock traded up $8.40 during midday trading on Thursday, reaching $454.74. 2,395 shares of the company were exchanged, compared to its average volume of 422,976. The business has a 50-day moving average price of $420.18 and a two-hundred day moving average price of $360.80. The firm has a market capitalization of $22.92 billion, a price-to-earnings ratio of 57.52, a price-to-earnings-growth ratio of 3.07 and a beta of 1.14. Charles River Laboratories International, Inc. has a one year low of $205.97 and a one year high of $450.84. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.36 and a quick ratio of 1.15.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Tuesday, August 3rd. The medical research company reported $2.61 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.38 by $0.23. The company had revenue of $914.61 million during the quarter, compared to analysts’ expectations of $880.72 million. Charles River Laboratories International had a net margin of 12.10% and a return on equity of 23.59%. Charles River Laboratories International’s quarterly revenue was up 34.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.58 earnings per share. As a group, analysts anticipate that Charles River Laboratories International, Inc. will post 10.25 earnings per share for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery & Safety Assessment and Manufacturing Support.

Further Reading: How to Use the MarketBeat Retirement Calculator

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.